These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 22718450

  • 1. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].
    Cravedi P.
    G Ital Nefrol; 2012; 29(3):274-82; discussion 292. PubMed ID: 22718450
    [Abstract] [Full Text] [Related]

  • 2. Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases.
    Manrique J, Cravedi P.
    Nefrologia; 2014 May 21; 34(3):388-97. PubMed ID: 24798567
    [Abstract] [Full Text] [Related]

  • 3. [Monoclonal antibodies in nephrology: a delicate balance between curative potential, evidence of effectiveness, and toxicity].
    Magistroni R.
    G Ital Nefrol; 2012 May 21; 29(3):283-91; discussion 292. PubMed ID: 22718451
    [Abstract] [Full Text] [Related]

  • 4. [Immunosuppressive therapy of glomerulonephritis--controlled studies].
    Ferrari P, Frey FJ.
    Ther Umsch; 1993 Feb 21; 50(2):119-29. PubMed ID: 8456416
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of post-transplant glomerulonephritis].
    Sandrini S, Valerio F.
    G Ital Nefrol; 2008 Feb 21; 25 Suppl 44():99-106. PubMed ID: 19048593
    [Abstract] [Full Text] [Related]

  • 6. [An innovative approach to the treatment of immune-mediated glomerular diseases].
    Roccatello D.
    G Ital Nefrol; 2013 Feb 21; 30(1):. PubMed ID: 23832439
    [Abstract] [Full Text] [Related]

  • 7. B cell suppression in primary glomerular disease.
    Rood IM, Hofstra JM, Deegens JK, Wetzels JF.
    Adv Chronic Kidney Dis; 2014 Mar 21; 21(2):166-81. PubMed ID: 24602466
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Diagnostic tests and treatment options in glomerular disease: 2014 update.
    Hogan J, Mohan P, Appel GB.
    Am J Kidney Dis; 2014 Apr 21; 63(4):656-66. PubMed ID: 24239051
    [Abstract] [Full Text] [Related]

  • 10. Drug insight: rituximab in renal disease and transplantation.
    Salama AD, Pusey CD.
    Nat Clin Pract Nephrol; 2006 Apr 21; 2(4):221-30. PubMed ID: 16932428
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases.
    Kattah AG, Fervenza FC, Roccatello D.
    Autoimmun Rev; 2013 Jun 21; 12(8):854-9. PubMed ID: 23000633
    [Abstract] [Full Text] [Related]

  • 13. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.
    Kronbichler A, Bruchfeld A.
    Nephron Clin Pract; 2014 Jun 21; 128(3-4):277-82. PubMed ID: 25401966
    [Abstract] [Full Text] [Related]

  • 14. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
    Mani LY, Vogt B, Burnier M, Golshayan D.
    Rev Med Suisse; 2011 Apr 13; 7(290):819-24. PubMed ID: 21595313
    [Abstract] [Full Text] [Related]

  • 15. [The immunosuppressive therapy of chronic (Bright's) nephritis].
    Krasnova TN, Shilov EM.
    Ter Arkh; 1993 Apr 13; 65(6):88-93. PubMed ID: 8378860
    [No Abstract] [Full Text] [Related]

  • 16. New diagnostic tests and new therapies for glomerular diseases.
    Appel GB, Appel AS.
    Blood Purif; 2013 Apr 13; 35(1-3):81-5. PubMed ID: 23343551
    [Abstract] [Full Text] [Related]

  • 17. Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.
    AlSahow A, Al-Muhaiteeb A, Nawar H, AlHelal B, AlYousef A, Abdallah E, AbuShall A, Elmekawi S, Meshal B, AlQallaf A, AlRajab H.
    Med Princ Pract; 2022 Apr 13; 31(2):133-141. PubMed ID: 35021170
    [Abstract] [Full Text] [Related]

  • 18. Rituximab in primary membranous nephropathy: first-line therapy, why not?
    Cravedi P, Remuzzi G, Ruggenenti P.
    Nephron Clin Pract; 2014 Apr 13; 128(3-4):261-9. PubMed ID: 25427622
    [Abstract] [Full Text] [Related]

  • 19. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X.
    Autoimmun Rev; 2012 Jul 13; 11(9):646-52. PubMed ID: 22146313
    [Abstract] [Full Text] [Related]

  • 20. Use of mycophenolic acid in non-transplant renal diseases.
    Stassen PM, Kallenberg CG, Stegeman CA.
    Nephrol Dial Transplant; 2007 Apr 13; 22(4):1013-9. PubMed ID: 17307748
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.